Featured Articles

MS Pharma, a fast growing pharmaceutical company based in Jordanand operating across the Middle East, Turkey and Africa, announced that it has entered into an agreement to acquire 100%…
Read More...

Gilead Sciences Inc. and insitro announced today that the companies have entered into a strategic collaboration to discover and develop therapies for patients with nonalcoholic…
Read More...

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced the European Commission has approved Lynparza (olaparib) as a…
Read More...

WuXi Biologics, a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and…
Read More...

Concerto HealthAI announced that they have entered into a collaboration with Pfizer to advance work in Precision Oncology using Concerto HealthAI’s eurekaHealthTM platform, artificial…
Read More...

Regeneron Pharmaceuticals and Alnylam Pharmaceuticals announced a collaboration to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of…
Read More...

The first clinical trial of an innovative universal influenza vaccine candidate is examining the vaccine’s safety and tolerability as well as its ability to induce an immune response in…
Read More...

Sandoz, a Novartis division and a global leader in biosimilars, today resubmission of its Biologics License Application (BLA) for a proposed biosimilar pegfilgrastim to the US Food and…
Read More...

Novartis announced that the US Food and Drug Administration (FDA) has approved Mayzent (siponimod) for the treatment of adults with relapsing forms of multiple sclerosis, including…
Read More...

MilliporeSigma officially opened its new M Lab Collaboration Center in Molsheim, France. The center is MilliporeSigma's first in Europe and ninth worldwide, providing biopharmaceutical…
Read More...

Merck announced the signing of a non-binding Memorandum of Understanding with Chinese biotech company GenScript for a strategic alliance focusing on plasmid and viral vector…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial…
Read More...

TESARO, an oncology-focused business acquired by GlaxoSmithKline plc, announced the presentation of data from the Phase 1/2 GARNET study evaluating dostarlimab in women with recurrent…
Read More...

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and EMA. Nintedanib…
Read More...

Iktos announced a collaboration agreement with Merck KGaA, Darmstadt, Germany where Iktos generative modelling artificial intelligence (AI) technology will be used to facilitate the…
Read More...

Patients with HER2-positive breast cancer face something of a predicament: The most effective drug to treat the cancer is also the most toxic. Trastuzumab, sold under the brand name…
Read More...

Roche announced that the European Commission has approved MabThera® (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare condition…
Read More...

Roche announced that the European Commission has approved Hemlibra (emicizumab) for routine prophylaxis of bleeding episodes in people with severe haemophilia A (congenital factor VIII…
Read More...

Seres Therapeutics announced a three-year research collaboration with AstraZeneca. The collaboration will focus on advancing mechanistic understanding of the microbiome in augmenting…
Read More...

Pfizer Inc. announced the United States (U.S.) Food and Drug Administration (FDA) has approved TRAZIMERA (trastuzumab-qyyp), a biosimilar to Herceptin (trastuzumab), for the treatment…
Read More...